Double-Action antibody takes on Hard-to-Treat neuroendocrine cancers

NCT ID NCT05879055

Ongoing Disease control Sponsor: Biotheus Inc. Source: ClinicalTrials.gov ↗

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This phase II trial tests a new drug called PM8002, a bispecific antibody that targets two proteins (PD-L1 and VEGF) involved in tumor growth and immune evasion. It is given together with standard chemotherapy (FOLFIRI) to people with advanced neuroendocrine tumors that have worsened after initial platinum-based chemotherapy. The study aims to see if the combination can shrink tumors and control the disease, while monitoring side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PM8002 (a bispecific antibody targeting PD-L1 and VEGF) combined with FOLFIRI chemotherapy
What this could lead to: If successful, this combination could offer a new second-line treatment option for people with aggressive neuroendocrine tumors that have stopped responding to initial chemotherapy.
What could go wrong: This is an early phase II study with only 31 participants, so results may not apply to all patients. The combination may cause side effects, and the treatment may not shrink tumors or improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroendocrine carcinoma neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROENDOCRINE NEOPLASM

Contacts and locations

Show contact details

Locations

Chinese PLA General Hospital

Beijing, China
Chongqing University Cancer Hospital

Chongqing, Chongqing Municipality, China
Fujian Province Cancer Hospital

Fuzhou, Fujian, China
Harbin Medical University Cancer Hospital

Harbin, Heilongjiang, China
Hunan Cancer Hospital

Changsha, Hunan, China
Jingzhou First People's Hospital

Jingzhou, Hubei, China
Nanjing Drum Tower Hospital

Nanjing, Jiangsu, China
Shandong Cancer Hospital

Jinan, Shandong, China
The Central Hospital of Yongzhou

Yongzhou, Hunan, China
The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, China
Union Hospital Tongji Medical College of Hust

Wuhan, Hubei, China
Yunnan Cancer Hospital (The Third Affiliated Hospital of Kunming Medical University)

Kunming, Yunnan, China
ZhongShan Hospital Fudan University

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.